References: |
1. Gniadecki, R., et al. "The optimal use of bexarotene in cutaneous T-cell lymphoma." Br. J. Dermatol. 157:433-440 (2007). 2. Rigas, J.R. and Dragnev, K.H. "Emerging Role of Rexinoids in Non-Small Cell Lung Cancer: Focus on Bexarotene." The Oncologist 10:22-33 (2005). 3. Wu, K., et al. "The retinoid X receptor-selective retinoid, LGD1069, prevents the development of estrogen receptor-negative mammary tumors in transgenic mice." Cancer Res. 62:6376-6380 (2002). 3. Ye,n W.C. and Lamph, W.W. "A selective retinoid X receptor agonist bexarotene (LGD1069, Targretin) prevents and overcomes multidrug resistance in advanced prostate cancer." Prostate 66:305-316 (2006). 4. Yen, W.C. and Lamph, W.W. "The selective retinoid X receptor agonist bexarotene (LGD1069, Targretin) prevents and overcomes multidrug resistance in advanced breast carcinoma." Mol. Cancer Ther. 4:824-834 (2005). 5. Yen, W.C., et al. "A selective retinoid X receptor agonist bexarotene (Targretin) prevents and overcomes acquired paclitaxel (Taxol) resistance in human non-small cell lung cancer." Clin. Cancer Res. 10:8656-8664 (2004). |